No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

By Sarich T.C.  

Clinical Pharmacokinetics, Vol. 42, Iss. 5, 2003-01 ,pp. : 485-492

Adis International

Access to resources Recommend Favorite

Comparable Pharmacokinetics and Pharmacodynamics of Melagatran in Japanese and Caucasian Volunteers after Oral Administration of the Direct Thrombin Inhibitor Ximelagatran

By Wernevik Linda C.  

Clinical Pharmacokinetics, Vol. 45, Iss. 1, 2006-01 ,pp. : 85-94

Adis International

Access to resources Recommend Favorite

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

By Johansson L.C.   Andersson M.   Fager G.   Gustafsson D.   Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 5, 2003-01 ,pp. : 475-484

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral Ximelagatran: A Population Model Analysis

By Eriksson Ulf G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 7, 2003-01 ,pp. : 687-701

Adis International

Access to resources Recommend Favorite

Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy

By  

Letters in Drug Design & Discovery, Vol. 2, Iss. 7, 2005-11 ,pp. : 503-506

Bentham Science Publishers

Access to resources Recommend Favorite